Skip Navigation


JAC Advance Access originally published online on March 13, 2008
Journal of Antimicrobial Chemotherapy 2008 61(6):1359-1361; doi:10.1093/jac/dkn103
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
61/6/1359    most recent
dkn103v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pulido, F.
Right arrow Articles by Arribas, J. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pulido, F.
Right arrow Articles by Arribas, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression

Federico Pulido1,{dagger},*, Rafael Delgado2, Ignacio Pérez-Valero3, Juan González-García3, Pilar Miralles4, Alberto Arranz5, Asunción Hernando1,6 and José R. Arribas3,{dagger}

1 Unidad HIV, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain; 2 Laboratorio de Microbiología Molecular, Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain; 3 Servicio de Medicina Interna, Hospital La Paz, Universidad Autónoma de Madrid, Madrid, Spain; 4 Hospital Gregorio Marañón, Madrid, Spain; 5 Hospital Príncipe de Asturias, Alcalá de Henares, Spain; 6 Dpto. Especialidades Medicas, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain

Received 26 November 2007; returned 20 January 2008; revised 28 January 2008; accepted 17 February 2008

* Correspondence address. Unidad HIV, Hospital 12 de Octubre, Av. de Córdoba s/n, 28041 Madrid, Spain. Tel: +34-91-390-82-02; Fax: +34-91-390-86-14; E-mail: pulidof{at}gmail.com

Objectives: Data are scarce on the long-term efficacy of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression. Four years of results of patients randomized to monotherapy in the Only Kaletra (OK) pilot clinical trial are presented.

Patients and methods: Twenty-one HIV-infected patients with suppressed HIV replication (<50 copies/mL) for at least 6 months and without previous failure while receiving a protease inhibitor-based regimen started lopinavir/ritonavir monotherapy. Follow-up was performed within the OK pilot clinical trial during the first 2 years and according to routine clinical practice during the 3rd and 4th years.

Results: Fourteen patients (67%) remain on monotherapy and with RNA <50 copies/mL (intention-to-treat analysis, with missing patients scored as failures). Five patients (24%) had virological rebound and all of them were successfully re-suppressed by adding two nucleosides. No major protease inhibitor mutations were found.

Conclusions: Our data support the long-term efficacy and safety of lopinavir/ritonavir monotherapy for the maintenance of HIV suppression, a finding that must be confirmed in larger studies.

Keywords: simplification , boosted protease inhibitors , antiretroviral therapy

{dagger} F. P. and J. R. A. contributed equally to this study.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.